menu
    • menu

    Company profile for DEPOMED INC

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently mark...
    Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda. In addition to its ability to develop and commercialize new drugs, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners and the technology is currently being used in four marketed drugs, including Gralise. Going forward, the company’s strategy is to continue to identify, license and develop new products that offer enhanced therapeutic options to patient populations that may be underserved by existing therapies. In addition, the company seeks to continue to leverage its innovative Acuform technology to generate a complementary stream of license revenue.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    DEPOMED INCUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7999 Gateway Blvd.
    Telephone
    Telephone
    510-744-8000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    This arthritis drug cost $198 in 2008. Now it's more than $10,000
    This arthritis drug cost $198 in 2008. Now it's more than $10,000

    19 Oct 2021

    // Bob Herman AXIOS

    https://www.axios.com/indocin-suppository-drug-prices-assertio-zyla-egalet-3278e307-d900-475c-92c9-8e5ff828a7da.html

    Bob Herman AXIOS
    19 Oct 2021
    Share Share
    Medivir taps ex-Acadia chief Uli Hacksell as interim CEO; Merck onboards CDO
    Medivir taps ex-Acadia chief Uli Hacksell as interim CEO; Merck onboards CDO

    19 Oct 2018

    // Amber Tong ENDPTS

    https://endpts.com/medivir-taps-ex-acadia-chief-uli-hacksell-as-interim-ceo-merck-onboards-chief-digital-officer/

    Amber Tong ENDPTS
    19 Oct 2018
    Share Share
    Ron Menezes joins Almirall’s Aqua Pharmaceuticals
    Ron Menezes joins Almirall’s Aqua Pharmaceuticals

    23 Aug 2017

    // PMLIVE

    http://www.pmlive.com/pharma_appointments/ron_menezes_joins_almiralls_aqua_pharmaceuticals_1202790

    PMLIVE
    23 Aug 2017
    Share Share
    Senate probe keeps heat on J&J, Mylan, Depomed,others for their opioid marketing
    Senate probe keeps heat on J&J, Mylan, Depomed,others for their opioid marketing

    30 Mar 2017

    // Eric Sagonowsky FIERCE PHARMA

    http://www.fiercepharma.com/pharma/senator-calls-for-answers-from-j-j-mylan-depomed-and-others-opioid-marketing-practices

    Eric Sagonowsky FIERCE PHARMA
    30 Mar 2017
    Share Share
    Another exec departs troubled Endo--and this time, it's for another drugmaker
    Another exec departs troubled Endo--and this time, it's for another drugmaker

    21 Oct 2016

    // FIERCE PHARMA

    http://www.fiercepharma.com/pharma/another-exec-departs-troubled-endo-and-time-it-s-for-another-drugmaker

    FIERCE PHARMA
    21 Oct 2016
    Share Share
    Card-carrying pharma reps? Chicago eyes licensing for painkiller promoters
    Card-carrying pharma reps? Chicago eyes licensing for painkiller promoters

    19 Oct 2016

    // Tracy Staton FIERCE PHARMA

    http://www.fiercepharma.com/pharma/card-carrying-pharma-reps-chicago-eyes-licensing-for-painkiller-promoters

    Tracy Staton FIERCE PHARMA
    19 Oct 2016
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search